


-49-

CLAIMS

What is claimed is:

1. Compounds having the Formula I:



I


- 5 or the pharmaceutically acceptable salts thereof,
wherein

X is phenyl or substituted phenyl;

Y is phenyl, substituted phenyl, pyridyl, or substituted pyridyl;

wherein substituted phenyl and substituted pyridyl can have from 1 to

- 10 4 substituents, each independently selected from -OC₁-C₁₂alkyl,



15

$\begin{array}{c} \text{O} \\ \parallel \\ \text{O} \end{array}$ $\begin{array}{c} \text{O} \\ \parallel \\ \text{O} \end{array}$
-CO₂H, -CO₂R¹, -NO₂, -CF₃, -CN, -NR¹R², -(CH₂)_nCO₂H,
-(CH₂)_nCO₂R¹, -SO₂NR¹R², tetrazole, -(CH₂)_n-tetrazole,
decahydroisoquinoline, imidazole, -(CH₂)_n imidazole, -CH=CH-
tetrazole, -CH=CH-imidazole, or phenyl;

- 20 R¹ and R² independently are hydrogen or C₁-C₆alkyl; and
each n is independently 0 to 5 inclusive.

R'' is hydrogen, C₁-C₆alkyl, or phenyl; and

R' is hydrogen, C₁-C₆alkyl, -CF₃, or phenyl.


- 25 2. A compound in accordance with Claim 1 wherein

X is substituted phenyl and the substituted phenyl has from 1 to

3 substituents independently selected from -OC₁-C₆alkyl, halogen,
C₁-C₆alkyl, -CF₃, or phenyl.

-50-

3. A compound in accordance with Claim 1 wherein
Y is substituted phenyl and the substituted phenyl has from 1 to
3 substituents independently selected from $-\text{CO}_2\text{H}$, $-\text{NO}_2$,
 $-\text{OC}_1\text{-C}_{12}$ alkyl, $-\text{CN}$, tetrazole, $-(\text{CH}_2)_n\text{CO}_2\text{H}$, $-\text{SO}_2\text{NR}^1\text{R}^2$,
5 $-\text{CF}_3$, imidazole, $-(\text{CH}_2)_n$ -tetrazole, $-(\text{CH}_2)_n$ imidazole, $-\text{CH}=\text{CH}$ -
tetrazole, or $-\text{CH}=\text{CH}$ -imidazole.
4. A compound in accordance with Claim 1 wherein
Y is substituted phenyl and the substituted phenyl has from 1 to
3 substituents, one of which is selected from $-\text{CO}_2\text{H}$.
- 10 5. A compound in accordance with Claim 4 wherein the $-\text{CO}_2\text{H}$ group is
located at the 2-position of the phenyl ring.
6. A compound in accordance with Claim 2 wherein the substituted phenyl
has two chlorine substituents located at the 3 and 4 positions of the phenyl
ring.
- 15 7. Compounds having the Formula I:



I

or the pharmaceutically acceptable salts thereof,

wherein

X is phenyl or substituted phenyl,

- 20 wherein when X is substituted phenyl, the substituted phenyl has from 1 to
4 substituents independently selected from $-\text{OC}_1\text{-C}_6$ alkyl, halogen,
 $\text{C}_1\text{-C}_6$ alkyl, $-\text{CF}_3$, or phenyl;

Y is phenyl or substituted phenyl,

- 25 wherein when Y is substituted phenyl, the substituted phenyl has from 1 to
4 substituents independently selected from $-\text{CO}_2\text{H}$, $-\text{NO}_2$,

-51-

-OC₁-C₁₂alkyl, -CN, -CF₃, -(CH₂)_nCO₂H, -SO₂NR¹R²,
tetrazole, -(CH₂)_n-tetrazole, imidazole, -(CH₂)_n imidazole,
-CH=CH-tetrazole, or -CH=CH-imidazole;

R¹ and R² independently are hydrogen or C₁-C₆alkyl; and
each n is independently 0 to 5 inclusive.

8. The compounds:

2-[2-(2,3,4-Trimethoxy-phenyl)-2,3-dihydro-1H-isoindol-
5-ylamino]benzoic acid;

5-Nitro-2-[2-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-isoindol-
5-ylamino]benzoic acid;

4-Methoxy-5-nitro-2-[2-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-
isoindol-5-ylamino]benzoic acid;

2-[2-(3,4-Dichlorophenyl)-2,3-dihydro-1H-isoindol-
5-ylamino]benzoic acid;

2-[2-(3,4-Dichlorophenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
5-nitro-benzoic acid;

2-[2-(3,4-Dichlorophenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
4-methoxy-5-nitro-benzoic acid;

2-[2-(3-Chlorophenyl)-2,3-dihydro-1H-isoindol-5-ylamino]benzoic
acid;

2-[2-(4-Chlorophenyl)-2,3-dihydro-1H-isoindol-5-ylamino]benzoic
acid;

2-[2-(3,4-Dimethylphenyl)-2,3-dihydro-1H-isoindol-
5-ylamino]benzoic acid;

2-[2-(4-Chloro-3-trifluoromethylphenyl)-2,3-dihydro-1H-isoindol-
5-ylamino]benzoic acid;

2-[2-Biphenyl-4-yl-2,3-dihydro-1H-isoindol-5-ylamino]benzoic
acid; or

2-[2-(3-Chlorophenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
nitro-benzoic acid.

-52-

9. The compounds:

- 2-(2-Phenyl-2,3-dihydro-1H-isoindol-5-ylamino)-benzoic acid;
5-Nitro-2-(2-phenyl-2,3-dihydro-1H-isoindol-5-ylamino)-benzoic
acid;
5 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
benzonitrile;
[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-yl]-(2-
tetrazol-1-yl-phenyl)-amine;
{2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
10 phenyl}-acetic acid;
3-{2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-
ylamino]-phenyl}-propionic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-6-
nitro-benzoic acid;
15 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-
nitro-benzoic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-3-
nitro-benzoic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
20 methanesulfonyl-benzoic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
sulfamoyl-benzoic acid;
4-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
isophthalic acid;
25 3-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
phthalic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
trifluoromethyl-benzoic acid;
2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
30 imidazol-1-yl-benzoic acid;
[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-yl]-(2-
tetrazol-1-ylmethyl-phenyl)-amine;

-53-

[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-yl]-[2-(2-tetrazol-1-yl-ethyl)-phenyl]-amine;

[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-yl]-[2-(2-tetrazol-1-yl-vinyl)-phenyl]-amine;

5 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-methyl-benzoic acid; or

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-3-methyl-benzoic acid.

10. The compounds:

10 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-nitro-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-3,5-dinitro-benzoic acid;

15 3-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-2-methyl-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-methoxy-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-propoxy-benzoic acid;

20 4-Butoxy-2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-pentyloxy-benzoic acid;

25 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-hexyloxy-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-heptyloxy-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-octyloxy-benzoic acid;

30 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-nonyloxy-benzoic acid;

-54-

4-Decyloxy-2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-4-isopropoxy-benzoic acid;

5 2-[2-(4-Chloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

2-[2-(4-Chloro-3-trifluoromethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

10 2-(2-Biphenyl-4-yl-2,3-dihydro-1H-isoindol-5-ylamino)-5-nitro-benzoic acid; or

2-[2-(3,4-Dimethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid.

11. The compounds:

15 2-[2-(3,4-Dimethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

2-(2-Phenyl-2,3-dihydro-1H-isoindol-5-ylamino)-benzoic acid.

2-[2-(3-Chloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

20 2-[2-(4-Chloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid

[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-yl]-[2-(1H-tetrazol-5-yl)-phenyl]-amine;

5-Amino-2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

25 5-Nitro-2-(2-phenyl-2,3-dihydro-1H-isoindol-5-ylamino)-benzoic acid;

2-[2-(4-Chloro-3-trifluoromethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

30 2-[2-(3-Fluoro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

2-[2-(3-Methoxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-nitro-benzoic acid;

-55-

2-[2-(3-Fluoro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
fluoro-benzoic acid; and

5 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
nicotinic acid.

12. The compounds:

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
methoxy-benzoic acid;

10 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-3-
nitro-benzoic acid;

3-Nitro-2-{2-[(4aS,8aR)-4-(octahydro-isoquinolin-2-yl)-phenyl]-
2,3-dihydro-1H-isoindol-5-ylamino}-benzoic acid;

15 2-{2-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-phenyl]-2,3-
dihydro-1H-isoindol-5-ylamino}-benzoic acid;

4-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
nicotinic acid;

2-[2-(4-Dibutylamino-phenyl)-2,3-dihydro-1H-isoindol-5-
ylamino]-benzoic acid;

20 2-[2-(3-Dibutylamino-phenyl)-2,3-dihydro-1H-isoindol-5-
ylamino]-benzoic acid;

2-[2-(3-Bromo-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
benzoic acid;

25 2-[2-(2-Chloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
benzoic acid;

5-Dibutylamino-2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-
isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-5-
methoxy-benzoic acid;

30 4-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-
isophthalic acid;

-56-

2-(2-Biphenyl-4-yl-2,3-dihydro-1H-isoindol-5-ylamino)-benzoic acid;

2-[2-(3,4-Dimethoxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

5 2-[2-(3,4-Dihydroxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4-Difluoro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

10 2-[2-(3-Fluoro-4-methyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4,5-Trihydroxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(4-Methyl-3-trifluoromethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

15 2-[2-(3,5-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(2,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

20 2-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid;

2-[2-(3,4,5-Trimethoxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzonitrile; or

2-[2-(3-Methoxy-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid.

25 13. A pharmaceutical composition comprising a compound of Claim 1 together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.

14. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.


30

-57-

15. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid proteins an amyloid protein aggregation inhibiting amount of a compound of Claim 1.

5 16. A method of imaging amyloid deposits, the method comprising the steps of:

a. introducing into a patient a detectable quantity of a labeled compound of Formula I



I

10 or a pharmaceutically acceptable salts thereof,

wherein

X is phenyl or substituted phenyl;

Y is phenyl, substituted phenyl, pyridyl, or substituted pyridyl;

wherein substituted phenyl and substituted pyridyl can have from 1 to

15 4 substituents, each independently selected from -OC₁-C₁₂alkyl, halogen, -C₁-C₆alkyl, phenyl, -CO₂H, -CO₂R¹, -NO₂, -CF₃, -CN,

20 $\begin{array}{cccc} \text{O} & \text{O} & \text{O} & \text{O} \\ || & || & || & || \\ -\text{CNHR}'' & , -\text{CNH-S-R}' & , -\text{S-R}' & , -\text{NR}^1\text{R}^2 & , -(\text{CH}_2)_n\text{CO}_2\text{H}, \end{array}$

$\begin{array}{cc} || & || \\ \text{O} & \text{O} \end{array}$
 -(CH₂)_nCO₂R¹, -SO₂NR¹R², tetrazole, -(CH₂)_n-tetrazole, decahydroisoquinoline, imidazole, -(CH₂)_n imidazole, -CH=CH-tetrazole, phenyl or -CH=CH-imidazole;

25 R¹ and R² independently are hydrogen or C₁-C₆alkyl; and each n is independently 0 to 5 inclusive.

R'' is hydrogen, C₁-C₆alkyl, or phenyl;

R' is hydrogen, C₁-C₆alkyl, -CF₃, or phenyl;

-58-

- b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
 - c. detecting the labeled compound associated with the amyloid deposits.
- 5
17. The method of Claim 16 wherein the patient has or is suspected to have Alzheimer's disease.
18. The method of Claim 16 wherein the labeled compound is a radiolabeled compound.
- 10 19. The method of Claim 16 wherein the labeled compound is detected using MRI.